nach oben

Erschienen in:

03.05.2019 | Observational Research

Dynamics of body mass index and visceral adiposity index in patients with rheumatoid arthritis treated with tofacitinib

verfasst von: Diana S. Novikova, Helen V. Udachkina, Eugenia I. Markelova, Irina G. Kirillova, Anna S. Misiyuk, Natalia V. Demidova, Tatiana V. Popkova

Erschienen in: Rheumatology International | Ausgabe 7/2019

Einloggen, um Zugang zu erhalten

Abstract

The increase in cardiovascular risk in patients with rheumatoid arthritis (RA) compared with the general population is due to the combined effect of traditional risk factors for cardiovascular diseases, metabolic disorders, systemic inflammation, and side effects of antirheumatic drugs. Tofacitinib (TOFA) is an oral reversible inhibitor of janus kinases for the treatment of RA with proven efficacy and good tolerability, but its effects on body weight and metabolic profile need to be clarified. We investigated the effects of TOFA on body mass index (BMI) and visceral adiposity index (VAI) in RA patients. Thirty-one consecutive patients with active RA and starting new treatment with TOFA were included in a prospective 1 year follow-up observational study of cardiovascular effects of TOFA treatment. Weight, height, waist circumference, BMI, blood pressure, lipid profile, fasting glucose and VAI were measured at baseline and 12 months of treatment. Median weight gain was 3 kg (4.2%) after 1 year of TOFA. 23 (74%) patients suffered from a weight gain, and 6 (26%) out of them from a weight increment of 10% or more. Patients with lower BMI (p = 0.024) and higher baseline DAS28 [ESR] (p = 0.017) have the risk of an increase in BMI > 5% during TOFA treatment in a multivariate analysis. A decrease in VAI after 12 months was recorded. Weight increment and improvement of VAI are frequent on TOFA treatment. BMI dynamics associated with higher disease activity at baseline and lower baseline BMI.

Agca R, Heslinga SC, Rollefstad S et al (2017) EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. Ann Rheum Dis 76:17–28CrossRefPubMed

Crowson CS, Matteson EL, Davis III JM, Gabriel SE (2013) Contribution of obesity to the rise in incidence of rheumatoid arthritis. Obesity fuels the upsurge in rheumatoid arthritis. Arthr Care Res 65(1):71–77

Qin B, Yang M, Fu H et al (2015) Body mass index and the risk of rheumatoid arthritis: a systematic review and dose-response meta-analysis. Arthritis Res Ther 17:86CrossRefPubMedPubMedCentral

Galic S, Oakhill JS, Steinberg GR (2010) Adipose tissue as an endocrine organ. Mol Cell Endocrinol 316(2):129–139CrossRef

Symmons DP, Bankhead CR, Harrison BJ et al (1997) Blood transfusion, smoking, and obesity as risk factors for the development of rheumatoid arthritis: results from a primary care-based incident case-control study in Norfolk, England. Arthr Rheum 40:1955–1961CrossRef

Dar L, Tiosano S, Watad A et al (2017) Are obesity and rheumatoid arthritis interrelated? Int J Clin Pract. https://doi.org/10.1111/ijcp.13045 CrossRefPubMed

Albrecht K, Richter A, Callhoff J et al (2016) Body mass index distribution in rheumatoid arthritis: a collaborative analysis from three large German rheumatoid arthritis databases. Arthritis Res Ther 18:149CrossRefPubMedPubMedCentral

Ajeganova S, Andersson ML, Hafstrom I (2013) Association of obesity with worse disease severity in rheumatoid arthritis as well as with comorbidities: A long-term followup from disease onset. Arthr Care Res 65(1):78–87CrossRef

Humphreys JH, Verstappen SM, Mirjafari H et al (2013) Association of morbid obesity with disability in early inflammatory polyarthritis: Results from the Norfolk Arthritis Register. Arthr Care Res 65(1):122–126CrossRef

10.

Vidal C, Barnetche T, Morel J, Combe B, Daien C (2015) Association of body mass index categories with disease activity and radiographic joint damage in rheumatoid arthritis: a systematic review and metaanalysis. J Rheumatol 42(12):2261–2269CrossRefPubMed

11.

George MD, Østergaard M, Conaghan PG, Emery P, Baker DG, Baker JF (2016) Obesity and rates of clinical remission and low MRI inflammation in rheumatoid arthritis. Ann Rheum Dis 76(10):1743–1746CrossRef

12.

van der Helm-van Mil AH, van der Kooij SM, Allaart CF et al (2008) A high body mass index has a protective effect on the amount of joint destruction in small joints in early rheumatoid arthritis. Ann Rheum Dis 67(6):769–774CrossRefPubMed

13.

Joo YB, Bang SY, Ryu JA et al (2017) Predictors of severe radiographic progression in patients with early rheumatoid arthritis: Prospective observational cohort study. Int J Rheum Dis 20(10):1437–1446CrossRefPubMed

14.

Escalante A, Haas RW, del Rincon I (2005) Paradoxical effect of body mass index on survival in rheumatoid arthritis: role of comorbidity and systemic inflammation. Arch Intern Med 165(14):1624–1629CrossRefPubMed

15.

Wolfe F, Michaud K (2012) Effect of body mass index on mortality and clinical status in rheumatoid arthritis. Arthritis Care Res (Hoboken) 64(10):1471–1479CrossRef

16.

Mikuls TR, Fay BT, Michaud K et al (2011) Associations of disease activity and treatments with mortality in men with rheumatoid arthritis: results from the VARA registry. Rheumatology (Oxford) 50(1):101–109CrossRef

17.

Baker JF, Billig E, Michaud K et al (2015) Weight loss, the obesity paradox, and the risk of death in rheumatoid arthritis. Arthritis Rheumatol 67(7):1711–1717CrossRefPubMedPubMedCentral

18.

Sparks JA, Chang SC, Nguyen US et al (2018) Weight change in the early rheumatoid arthritis period and risk for subsequent mortality among women with RA and matched comparators. Arthritis Rheumatol 70(1):18–29CrossRefPubMed

19.

George MD, Baker JF (2016) The obesity epidemic and consequences for rheumatoid arthritis Care. Curr Rheumatol Rep 18(1):6CrossRefPubMedPubMedCentral

20.

England BR, Baker JF, Sayles H et al (2018) Body mass index, weight loss, and cause-specific mortality in rheumatoid arthritis. Arthritis Care Res (Hoboken) 70(1):11–18CrossRef

21.

Frasca D, Blomberg BB, Paganelli R (2017) Aging, obesity, and inflammatory age-related diseases. Front Immunol 8:1745CrossRefPubMedPubMedCentral

22.

Vlietstra L, Meredith-Jones K, Stebbings S et al (2017) Waters sarcopenic obesity is more prevalent in osteoarthritis than rheumatoid arthritis: are different processes involved? Rheumatology 56:18161818CrossRef

23.

Melmer A, Lamina C, Tschoner A et al (2013) Body adiposity index and other indexes of body composition in the SAPHIR study: association with cardiovascular risk factors. Obesity (Silver Spring) 21(4):775–781CrossRef

24.

Amato MC, Giordano C, Galia M, Criscimanna A, Vitabile S, Midiri M, Galluzzo A, AlkaMeSy Study Group (2010) Visceral Adiposity Index: a reliable indicator of visceral fat function associated with cardiometabolic risk. Diabetes Care 33:920–922CrossRef

25.

Amato MC, Giordano C, Pitrone M, Galluzzo A (2011) Cut-off points of the visceral adiposity index (VAI) identifying a visceral adipose dysfunction associated with cardiometabolic risk in a Caucasian Sicilian population. Lipids Health Dis 10:183CrossRefPubMedPubMedCentral

26.

Zhang Y, Lu N, Peloquin C, Dubreuil M et al (2017) Improved survival in rheumatoid arthritis: a general population-based cohort study. Ann Rheum Dis 76(2):408–413CrossRefPubMed

27.

Kerola AM, Nieminen TV, Virta LJ et al (2015) No increased cardiovascular mortality among early rheumatoid arthritis patients: a nationwide register study in 2000–2008. Clin Exp Rheumatol 33(3):391–398PubMed

28.

Holmqvist M, Ljung L, Askling J et al (2018) Mortality following new-onset rheumatoid arthritis: has modern rheumatology had an impact? Ann Rheum Dis 77(1):85–91CrossRef

29.

Mahe E, Reguia Z, Barthelemy H et al (2014) Evaluation of risk factors for body weight increment in psoriatic patients on infliximab: a multicentre, cross-sectional study. JEADV 28:151–159PubMed

30.

Alcorn N, Tierney A, Wu O, Gilmour H, Madhok R (2010) Impact of anti-tumour necrosis factor therapy on the weight of patients with rheumatoid arthritis. Ann Rheum Dis 69:1571CrossRefPubMed

31.

Brown RA, Spina D, Butt S, Summers GD (2012) Long-term effects of anti-tumour necrosis factor therapy on weight in patients with rheumatoid arthritis. Clin Rheumatol 31:455–461CrossRefPubMed

32.

Gisondi P, Cotena C, Tessari G, Girolomoni G (2008) Anti–tumour necrosis factor- α therapy increases body weight in patients with chronic plaque psoriasis: a retrospective cohort study. JEADV 22:341–344PubMed

33.

Younis S, Rosner I, Rimar D (2013) Interleukin 6 blockade-associated weight gain with abdominal enlargement in a patient with rheumatoid arthritis. J Clin Rheumatol 19(1):48–49PubMed

34.

Lee YH, Bae SC, Song GG (2015) Comparative efficacy and safety of tofacitinib, with or without methotrexate, in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials. Rheumatol Int 35(12):1965–1974CrossRefPubMed

35.

Charles-Schoeman C, Burmester G, Nash P et al (2016) Efficacy and safety of tofacitinib following inadequate response to conventional synthetic or biological disease-modifying antirheumatic drugs. Ann Rheum Dis 75(7):1293–1301CrossRefPubMed

36.

Cohen SB, Tanaka Y, Mariette X et al (2017) Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials. Ann Rheum Dis 76(7):1253–1262

37.

Charles-Schoeman C, Fleischmann R, Davignon J et al (2015) Potential mechanisms leading to the abnormal lipid profile in patients with rheumatoid arthritis versus healthy volunteers and reversal by tofacitinib. Arthritis Rheumatol 67(3):616–625CrossRefPubMedPubMedCentral

38.

Pérez-Baos S, Barrasa JI, Gratal P et al (2017) Tofacitinib restores the inhibition of reverse cholesterol transport induced by inflammation: understanding the lipid paradox associated with rheumatoid arthritis. Br J Pharmacol 174(18):3018–3031CrossRefPubMedPubMedCentral

39.

Kume K, Amano K, Yamada S et al (2017) Tofacitinib improves atherosclerosis despite up-regulating serum cholesterol in patients with active rheumatoid arthritis: a cohort study. Rheumatol Int 37(12):2079–2085CrossRefPubMed

40.

Aletaha D, Neogi T, Silman A et al (2010) The 2010 American College of Rheumatology/European League against rheumatism classification criteria for rheumatoid arthritis. Ann Rheum Dis 69:1580–1588CrossRef

41.

Van Gestel AM, Haagsma CJ, Van Riel PLCM (1998) Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. Arthritis Rheum 41:1845–1850CrossRefPubMed

42.

Alberti KG, Eckel RH, Grundy SM et al (2009) Harmonizing the Metabolic Syndrome A Joint Interim Statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120(16):1640–1645CrossRefPubMed

43.

Younis S, Rosner I, Rimar D et al (2013) Weight change during pharmacological blockade of interleukin-6 or tumor necrosis factor-α in patients with inflammatory rheumatic disorders: a 16-week comparative study. Cytokine 61:353–355CrossRefPubMed

44.

Engvall I-L, Tengstrand B, Brismar K, Hafström I (2010) Infliximab therapy increases body fat mass in early rheumatoid arthritis independently of changes in disease activity and levels of leptin and adiponectin: a randomised study over 21 months. Arthritis Res Ther 12:R197CrossRefPubMedPubMedCentral

45.

Briot K, Garnero P, Le Henanff A et al (2005) Body weight, body composition, and bone turnover changes in patients with spondyloarthropathy receiving anti-tumour necrosis factor a treatment. Ann Rheum Dis 64:1137–1140

46.

Tournadre A, Pereira B, Dutheil F et al (2017) Changes in body composition and metabolic profile during interleukin 6 inhibition in rheumatoid arthritis. J Cachexia Sarcopenia Muscle 8(4):639–646

47.

Mishra J, Verma R, Alpini G, Meng F, Kumar N (2015) Role of Janus Kinase 3 in Predisposition to Obesity-associated Metabolic Syndrome. J Biol Chem 290(49):29301–29312

48.

Al-Suhaimi EA, Shehzad A (2013) Leptin, resistin and visfatin: the missing link between endocrine metabolic disorders and immunity. Eur J Med Res 18:12CrossRefPubMedPubMedCentral

49.

Moisan A, Lee YK, Zhang JD et al (2015) White-to-brown metabolic conversion of human adipocytes by JAK inhibition. Nat Cell Biol 17(1):57–67CrossRefPubMed

Titel: Dynamics of body mass index and visceral adiposity index in patients with rheumatoid arthritis treated with tofacitinib
verfasst von: Diana S. Novikova
Helen V. Udachkina
Eugenia I. Markelova
Irina G. Kirillova
Anna S. Misiyuk
Natalia V. Demidova
Tatiana V. Popkova
Publikationsdatum: 03.05.2019
Verlag: Springer Berlin Heidelberg
Erschienen in: Rheumatology International / Ausgabe 7/2019
Print ISSN: 0172-8172
Elektronische ISSN: 1437-160X
DOI: https://doi.org/10.1007/s00296-019-04303-x

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2019

Indications for bone marrow examinations in rheumatology

Evidence synthesis of types and intensity of therapeutic land-based exercises to reduce pain in individuals with knee osteoarthritis

Immunohistochemical and ultrastructural analysis of sporadic inclusion body myositis: a case series

Implement statistics at each step of your research

Pain and gastrointestinal dysfunction are significant associations with psychiatric disorders in patients with Ehlers–Danlos syndrome and hypermobility spectrum disorders: a retrospective study